Abstract

Despite our ever-increasing ability to target the molecular and genetic pathways responsible for non–small cell lung cancer (NSCLC), anatomic surgical resection remains the mainstay of treatment for those without evidence of systemic disease. Although these procedures can be performed with relatively low mortality, the age and coexisting conditions of the population lends itself to a myriad of potential complications. Minimally invasive surgical approaches to the treatment of lung cancer hold the potential to offer curative resection to a much broader group of patients without compromising oncologic principles.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.